Survival of stage III non‐seminoma testis cancer patients versus simulated controls, according to race/ethnicity.

Background: It is unknown whether 5‐year overall survival (OS) differs and to what extent between the American Joint Committee on Cancer stage III non‐seminoma testicular germ cell tumor (NS‐TGCT) patients and simulated age‐matched male population‐based controls, according to race/ethnicity groups. Methods: We identified newly diagnosed (2004–2014) stage III NS‐TGCT patients within the Surveillance Epidemiology and End Results database 2004–2019. For each case, we simulated an age‐matched male control (Monte Carlo simulation), relying on Social Security Administration (SSA) Life Tables with 5 years of follow‐up. We compared OS rates between stage III NS‐TGCT patients and simulated age‐matched male population‐based controls, according to race/ethnicity groups (Caucasian, Hispanic, Asian/Pacific Islander and African American). Both, cancer‐specific mortality (CSM) and other‐cause mortality (OCM) were computed. Results: Of 2054 stage III NS‐TGCT patients, 60% were Caucasians versus 33% Hispanics versus 4% Asians/Pacific Islanders versus 3% African Americans. The 5‐year OS difference between stage III NS‐TGCT patients versus simulated age‐matched male population‐based controls was highest in Asians/Pacific Islanders (64 vs. 99%, Δ = 35%), followed by African Americans (66 vs. 97%, Δ = 31%), Hispanics (72 vs. 99%, Δ = 27%), and Caucasians (76 vs. 98%, Δ = 22%). The 5‐year CSM rate was highest in Asians/Pacific Islanders (32%), followed by African Americans (26%), Hispanics (25%), and Caucasians (20%). The 5‐year OCM rate was highest in African Americans (8%), followed by Caucasians (4%), Asians/Pacific Islanders (4%), and Hispanics (2%). Conclusion: Relative to SSA Life Tables, the highest 5‐year OS disadvantage applied to stage III NS‐TGCT Asian/Pacific Islander race/ethnicity group, followed by African American, Hispanic and Caucasian, in that order. [ABSTRACT FROM AUTHOR]